We are pleased to announce that, starting in April 2026, we have launched new ABC Transporter Vesicles derived from HEK cells, replacing the previous Sf9 cell–derived products.
Accordingly, the Sf9-derived vesicles will be discontinued as of the end of September 2026.
Please also note that, due to a manufacturing lead time of approximately three months, orders for made-to-order products will be accepted only until the end of June 2026.
Products
A recent trend in drug development is to create new drugs that target a specific molecule identified by means of a genomic approach. Nevertheless, many drugs fail to reach clinical application, and costs associated with such unsuccessful drugs are high.
One of the major reasons for drop-out is inappropriate ADME (absorption, distribution, metabolism, and excretion) properties ofcandidates, resulting in low bioavailability or toxicity. It is, therefore, important to predict such problems at as early a stage as possible in the development process. GenoMembrane provides transporter reagents for this purpose.
GenoMembrane provides Transporter Membrane Vesicles and transporter expressing cell lines as research reagents.
